CTRI/2013/07/003810Completed未知
Pharmacodynamic interaction study of Emblica officinalis (CAPROS)with clopidogrel and ecosprin in patients with type II diabetes mellitus.
AYUSH0 sites10 target enrollmentStarted: TBDLast updated:
Drugs
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients of either gender between 30-70 yrs, on stable dose of anti-diabetic medication (taking Metformin alone in dose between 1000-2500mg per day or in combination with glimiperide maximum 4 mg per day) as prescribed by the physician over past 8 weeks prior to screening visit and having HbA1c between 6.5-8% were enrolled in the study.
Exclusion Criteria
- •To avoid factors known to affect antiplatelet activity, the following exclusion criteria were applied: severe uncontrolled hyperglycemia, uncontrolled hypertension, cardiac arrhythmia, congestive heart failure, and evidence of hepatic and renal impairment or any other serious chronic disease requiring active treatment. Subjects hypersensitive to the study drugs were also excluded.
Investigators
Similar Trials
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Recruiting
Phase 3
Effects of Coadministration of Empagliflozin and Colchicine on Heart Failure.IRCT20111206008307N40Tabriz University of Medical Sciences50
Completed
Not Applicable
The pharmacokinetics and pharmacodynamics of eculizumab in patients with paroxysmal nocturnal hemoglobinuria.PNHrare blood disease10018849NL-OMON48010Radboud Universitair Medisch Centrum27
Active, not recruiting
Not Applicable
Study on the pharmacodynamic interactions between propofol and sevoflurane during induction of anesthesia.AnesthesiaEUCTR2005-004632-40-BEniversity Hospital Ghent60
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90